Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
TerminatedPhase 2Results postedLast updated 16 August 2022
What this trial tests
Phase 2 trial testing MT-3724 in Non-hodgkin Lymphoma in 9 participants. Terminated before completion.
Adults 18 to 101, any sex, with Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Part 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting ToxicityPrimary· Up to 1 year
An adverse event is any untoward medical occurrence or clinical investigation in a participant administered a pharmaceutical product(s) and which does not necessarily have to have a causal relationship with this experimental treatment(s). SAE is any untoward medical occurrence, at any dose; is fatal or life-threatening, is life-threatening, results in permanently disabling; results in unplanned in-patient hospitalization or prolongation of existing hospitalization; results in a congenital abnormality or birth defect; important medical events that may not result in death, be life-threatening, o
TEAEs
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
3
Part 1: MT-3724 25 mcg/Kg-LEN
3
Part 1: MT-3724 20 mcg/Kg-LEN
3
SAEs
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
1
Part 1: MT-3724 25 mcg/Kg-LEN
1
Part 1: MT-3724 20 mcg/Kg-LEN
1
DLT
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
0
Part 1: MT-3724 25 mcg/Kg-LEN
2
Part 1: MT-3724 20 mcg/Kg-LEN
0
Part 1 and 2: Number of Participants With Abnormal Laboratory ParametersPrimary· Up to 1 year
Laboratory parameters included hematology, blood chemistry, and urinalysis. Any abnormal laboratory test results which were considered clinically significant by the investigator were recorded on the case report form. Number of participants with any clinically significant abnormalities in laboratory parameters have been presented.
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
3
Part 1: MT-3724 25 mcg/Kg-LEN
3
Part 1: MT-3724 20 mcg/Kg-LEN
3
Part 1 and 2: Plasma Concentrations of MT-3724Secondary· Days 1,3 and 12 of treatment cycle (Each cycle is of 28 days); Up to 1 year
Blood samples were collected for Pharmacokinetic (PK) analysis of MT-3724. Data could not be calculated due to small sample size and inconsistent sampling as a result of early termination.
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
NA
± NA
Part 1: MT-3724 25 mcg/Kg-LEN
NA
± NA
Part 1: MT-3724 20 mcg/Kg-LEN
NA
± NA
Part 1 and 2: Change From Baseline in B-cell CountSecondary· Up to 1 year
Blood samples were collected for analysis of B-cell count. Data could not be calculated due to small sample size and inconsistent sampling as a result of early termination.
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
NA
± NA
Part 1: MT-3724 25 mcg/Kg-LEN
NA
± NA
Part 1: MT-3724 20 mcg/Kg-LEN
NA
± NA
Part 1 and 2: Number of Participants With Objective Response Rate (ORR)Secondary· Up to 1 year
ORR was defined as CR or Partial Response (PR). CR: a score 1 (no uptake above background), 2 (uptake \<=mediastinum), or 3 (\<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites with no new lesions and no evidence of FDG-avid disease in bone marrow. PR: a score 4 (uptake moderately greater than \[\>\] liver) or 5 (uptake markedly \>liver and/or new lesions) with reduced uptake compared with baseline and residual mass(es) of any size on PET 5-PS for lymph nodes and extralymphatic sites with no new lesions and reduced residual uptake i
PR
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
2
Part 1: MT-3724 25 mcg/Kg-LEN
0
Part 1: MT-3724 20 mcg/Kg-LEN
1
CR
Group
Value
95% CI
Part 1: MT-3724 10 mcg/Kg-LEN
1
Part 1: MT-3724 25 mcg/Kg-LEN
2
Part 1: MT-3724 20 mcg/Kg-LEN
1
Adverse events — posted to ClinicalTrials.gov
Time frame: All-cause mortality, non-serious TEAEs and SAEs were collected up to 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in participants with relapsed or refractory B-Cell NHL.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03488251 — PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of
· Phase 2
· terminated
NCT02715843 — Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
· no longer available
Other recruiting trials for Non-hodgkin Lymphoma
Currently open trials in the same condition.
NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
· Phase 1
· recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer
· Phase 2
· recruiting
NCT06299462 — PTCy and ATG for MSD and MUD Transplants
· Phase 1, PHASE2
· recruiting
NCT06393335 — Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory C
· EARLY_PHASE1
· recruiting
NCT06323525 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
· Phase 1, PHASE2
· recruiting
Other Molecular Templates, Inc. trials
Trials by the same sponsor.
NCT06034860 — Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
· Phase 1
· terminated
NCT04795713 — Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
· Phase 1
· terminated
NCT04017130 — A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 1
· terminated
NCT04029922 — Study of MT-5111 in HER2-positive Solid Tumors
· Phase 1
· terminated
NCT03488251 — PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of
· Phase 2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Molecular Templates, Inc.
Last refreshed: 16 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03645395.